The expanded indication allows Orchid SRV to be used with all IV access methods.
Orchid SRV is a sterile, single-use connector for needle-free access that makes a return to treatment quicker and more simple. It is indicated for use with central venous catheters, peripherally inserted central catheters, peripheral IV catheters and intraosseous cannulation. It can be used during direct injection, intermittent infusion and continuous infusion in patients two weeks of age and older.
“Maintaining vascular access is one of the most fundamental, yet most over-looked, treatment modalities in medicine today,” Cofounder and Chief Medical Officer Ryan Dennis said in a news release. “Expanding indication for the Orchid SRV to all IV settings will help improve outcomes for millions of patients every year.”
Dislodgement and associated IV treatment failures are costly and affect more than 342 million peripheral IV administrations in the U.S. per year. Dislodgement is most frequently caused by patient confusion or removal of a catheter, loose dressing or tape, or tubing becoming tangled in bed linens. According to Linear Health Sciences, clinical simulation testing of 360 Orchid SRVs showed that the device prevented IV dislodgment by 91.1%.
“The expanded indication from the FDA represents an acceleration of our commercialization efforts, as we look to create a continuum of care for vascular access,” Cofounder and CEO Dan Clark said. “In addition to improved care for patients, the Orchid SRV enables significant downstream cost savings, which benefits the entire healthcare ecosystem.”